NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
NCT03993912: Phase 3 - Lenalidomide & SC Daratumumab vs Lenalidomide and Dex in NDMM - (IFM2017_03)
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma
NCT03590652: Phase 2 - Daratumumab, Ixazomib, Pomalidomide + Dex as Salvage Therapy Refractory MM
NCT03652064 : Phase 3 - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM - MMY3019 CEPHEUS
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03710603: Phase 3 - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM (Perseus) EMN17
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT03556332: Phase 2 - Carfilzomib, Lenalidomide, Dex Daratumumab for relap. MM with auto transplant
NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
NCT03290950: Phase 2 - A Study of Daratumumab in Patients With NDMM wKRd-D - Manhattan Trial
NCT03277105: Phase 3 - Subcutaneous vs Intravenous daratumumab in relapsed MM - COLUMBA study
NCT03180736 : Phase 3 - EMN 14 - Pomalidomide and Dexa +/- Dara in relapsed MM - APOLLO study
NCT03158688: Phase 3 - Carfilzomib, Daratumumab and Dexa for relapsed Multiple Myeloma. (CANDOR)